keyword
MENU ▼
Read by QxMD icon Read
search

Cannabis and cannabinoids

keyword
https://www.readbyqxmd.com/read/29028489/assessment-of-types-of-synthetic-cannabinoids-in-narcotic-cases-assessed-by-the-council-of-forensic-medicine-between-2011-2015-ankara-turkey
#1
Ersin Göl, İsmet Çok
Synthetic cannabinoids mimic the effects of cannabis and are the largest and fastest growing class of newly appearing designer drugs. Reports have revealed that various types of synthetic cannabinoids are mixed with herbal substances. The present study investigated the herbal substance cases involving synthetic cannabinoids in Ankara and nearby cities in Turkey. Data were collected from the reports of synthetic cannabinoids that were analyzed between January 01, 2011 and December 31, 2015 in the Ankara Narcotic Department of the Council of Forensic Medicine at the request of the judicial authorities...
October 4, 2017: Forensic Science International
https://www.readbyqxmd.com/read/29025078/a-cloud-on-the-horizon-a-survey-into-the-use-of-electronic-vaping-devices-for-recreational-drug-and-new-psychoactive-substance-nps-administration
#2
M S Blundell, P I Dargan, D M Wood
Background: There is limited published scientific data on vaping recreational drugs other than cannabis. A recent review suggested that 15% of people vaping cannabis have also vaped a synthetic cannabinoid receptor agonist (SCRA) and identified over 300 Internet reports of e-liquid manufacture of recreational drugs and/or new psychoactive substances (NPS). Aim: To determine the prevalence of use of electronic vaping devices for recreational drug and NPS delivery in the UK...
September 14, 2017: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/29017688/cannabinoids-in-pain-management-and-palliative-medicine
#3
Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke
BACKGROUND: There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. METHODS: We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, and Medline...
September 22, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28986974/a-review-of-methods-for-the-chemical-characterization-of-cannabis-natural-products
#4
REVIEW
Allegra Leghissa, Zacariah L Hildenbrand, Kevin A Schug
Cannabis has garnered a great deal of new attention in the past couple of years in the United States due to the increasing instances of its legalization for recreational use and indications for medicinal benefit. Despite a growing number of laboratories focused on cannabis analysis, the separation science literature pertaining to the determination of cannabis natural products is still in its infancy despite the plant having been utilized by humans for nearly 30 000 years and it being now the most widely used drug world-wide...
October 7, 2017: Journal of Separation Science
https://www.readbyqxmd.com/read/28983880/cannabis-and-cannabinoids-for-chronic-pain
#5
REVIEW
E Alfonso Romero-Sandoval, Ashley L Kolano, P Abigail Alvarado-Vázquez
PURPOSE OF REVIEW: The purpose of this study was to provide the most up-to-date scientific evidence of the potential analgesic effects, or lack thereof, of the marijuana plant (cannabis) or cannabinoids, and of safety or tolerability of their long-term use. RECENT FINDINGS: We found that inhaled (smoked or vaporized) cannabis is consistently effective in reducing chronic non-cancer pain. Oral cannabinoids seem to improve some aspects of chronic pain (sleep and general quality of life), or cancer chronic pain, but they do not seem effective in acute postoperative pain, abdominal chronic pain, or rheumatoid pain...
October 5, 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28983686/8%C3%AE-oh-thc-and-8%C3%AE-11-dioh-thc-minor-metabolites-with-major-informative-value
#6
Angela Gasse, Heidi Pfeiffer, Helga Köhler, Jennifer Schürenkamp
The ∆9-tetrahydrocannabinol (THC) metabolites 8β-hydroxy-THC and 8β,11-dihydroxy-THC are mentioned in the literature as potential blood markers of recent cannabis use. However, the formation of these metabolites in in vivo detectable concentrations has been described controversially. Therefore, the aim of this study was to verify the in vivo metabolism of 8β-hydroxy-THC and 8β,11-dihydroxy-THC in order to evaluate their potential as blood markers of recent cannabis use. First, we developed and validated a solid-phase-extraction method coupled with gas chromatography-mass spectrometry in order to enable the selective and very sensitive determination of 8β-hydroxy-THC and 8β,11-dihydroxy-THC...
October 5, 2017: International Journal of Legal Medicine
https://www.readbyqxmd.com/read/28981118/overactive-type-2-cannabinoid-receptor-induces-meiosis-in-fetal-gonads-and-impairs-ovarian-reserve
#7
Emanuela De Domenico, Federica Todaro, Gabriele Rossi, Susanna Dolci, Raffaele Geremia, Pellegrino Rossi, Paola Grimaldi
Type 2 cannabinoid receptor (CB2R) has been proposed to promote in vitro meiotic entry of postnatal male germ cells and to maintain the temporal progression of spermatogenesis in vivo. However, no information is presently available on the role played by CB2R in male and female fetal gonads. Here we show that in vitro pharmacological stimulation with JWH133, a CB2R agonist, induced activation of the meiotic program in both male and female fetal gonads. Upon stimulation, gonocytes initiated the meiotic program but became arrested at early stages of prophase I, while oocytes showed an increased rate of meiotic entry and progression toward more advanced stage of meiosis...
October 5, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28976704/human-serum-albumin-a-modulator-of-cannabinoid-drugs
#8
Loris Leboffe, Alessandra di Masi, Viviana Trezza, Fabio Polticelli, Paolo Ascenzi
The endocannabinoid system is a unique neuromodulatory system that affects a wide range of biological processes and maintains the homeostasis in all mammal body systems. In recent years, several pharmacological tools to target endocannabinoid neurotransmission have been developed, including direct and indirect cannabinoid agonists and cannabinoid antagonists. Due to their hydrophobic nature, cannabinoid agonists and antagonists need to bind specific transporters to allow their distribution in body fluids. Human serum albumin (HSA), the most abundant plasma protein, is a key determinant of drug pharmacokinetics...
October 4, 2017: IUBMB Life
https://www.readbyqxmd.com/read/28975060/the-current-landscape-of-marijuana-and-pharmacogenetics
#9
EDITORIAL
Kerry Anne Rambaran, Michael Chu, Tyler B Johnson, Saeed K Alzghari
The treatment of medical conditions with cannabis and cannabinoid compounds is advancing. Although there are numerous reports related to the genetic variations of the cannabinoid receptor, a lack of studies that examine the relationship between other pharmacogenetic markers and health outcomes currently exists. Herein, we advocate for the legalization of marijuana in the United States in order to perform more randomized controlled trials to help elucidate the role of other pharmacogenetic targets and cannabis for use in clinical practice...
July 30, 2017: Curēus
https://www.readbyqxmd.com/read/28967368/is-cannabis-an-effective-treatment-for-joint-pain
#10
REVIEW
Richard J Miller, Rachel E Miller
Cannabis has been used to treat pain for thousands of years. However, since the early part of the 20th century, laws restricting cannabis use have limited its evaluation using modern scientific criteria. Over the last decade, the situation has started to change because of the increased availability of cannabis in the United States for either medical or recreational purposes, making it important to provide the public with accurate information as to the effectiveness of the drug for joint pain among other indications...
September 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28953512/emergency-department-treatment-of-cannabinoid-hyperemesis-syndrome-a-review
#11
Neera Khattar, Joanne C Routsolias
BACKGROUND: Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic vomiting associated with chronic cannabis use. As cannabis consumption steadily increases each year, CHS is becoming a commonplace and costly occurrence in hospitals nationwide. Currently, there are no best treatment strategies agreed upon universally. AREAS OF UNCERTAINTY: Thus far, most data about CHS have come from case reports and case series. Consequently, the pathophysiology of the syndrome is unclear, and its occurrence in some cannabis users, but not others, is not understood...
September 11, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28951549/cb1-receptor-activation-on-vglut2-expressing-glutamatergic-neurons-underlies-%C3%AE-9-tetrahydrocannabinol-%C3%AE-9-thc-induced-aversive-effects-in-mice
#12
Xiao Han, Yi He, Guo-Hua Bi, Hai-Ying Zhang, Rui Song, Qing-Rong Liu, Josephine M Egan, Eliot L Gardner, Jing Li, Zheng-Xiong Xi
Cannabis can be rewarding or aversive. Cannabis reward is believed to be mediated by activation of cannabinoid CB1 receptors (CB1Rs) on GABAergic neurons that disinhibit dopaminergic neurons in the ventral tegmental area (VTA). However, little is known about the mechanisms underlying cannabis aversion in rodents. In the present study, CB1Rs are found not only on VTA GABAergic neurons, but also on VTA glutamatergic neurons that express vesicular glutamate transporter 2 (VgluT2). We then used Cre-Loxp transgenic technology to selectively delete CB1Rs in VgluT2-expressing glutamatergic neurons (VgluT2-CB1 (-/-)) and Cre-dependent viral vector to express light-sensitive channelrhodopsin-2 into VTA glutamatergic neurons...
September 26, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28948486/efficacy-and-tolerability-of-phytomedicines-in-multiple-sclerosis-patients-a-review
#13
REVIEW
Mohammad Hosein Farzaei, Zahra Shahpiri, Roodabeh Bahramsoltani, Marjan Moghaddam Nia, Fariba Najafi, Roja Rahimi
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disorder of the central nervous system (CNS) that can cause cognition, mobility, and sensory impairments. It is considered one of the most common non-traumatic causes of disability in the world. The aim of the present article was to review the clinical evidence related to medicinal plants in the management of MS symptoms. Electronic databases, including the Cochrane Library, Pubmed, and Scopus, were searched for entries from 1966 to February 2017...
September 25, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28934780/efficacy-of-cannabis-based-medicines-for-pain-management-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#14
J Aviram, G Samuelly-Leichtag
BACKGROUND: The management of chronic pain is a complex challenge worldwide. Cannabis-based medicines (CBMs) have proven to be efficient in reducing chronic pain, although the topic remains highly controversial in this field. OBJECTIVES: This study's aim is to conduct a conclusive review and meta-analysis, which incorporates all randomized controlled trials (RCTs) in order to update clinicians' and researchers' knowledge regarding the efficacy and adverse events (AEs) of CBMs for chronic and postoperative pain treatment...
September 2017: Pain Physician
https://www.readbyqxmd.com/read/28930056/developmentally-specific-associations-between-cnr1-genotype-and-cannabis-use-across-emerging-adulthood
#15
James R Ashenhurst, K Paige Harden, Travis T Mallard, William R Corbin, Kim Fromme
OBJECTIVE: Previous studies have found preliminary evidence for associations between common single-nucleotide polymorphisms (SNPs) in the cannabinoid receptor gene CNR1 and cannabis use and dependence. The present study examined a set of eight independent SNPs in or near CNR1 in relation to cannabis use measured longitudinally across emerging adulthood. METHOD: Using latent growth curve modeling of 10 waves of longitudinal data spanning mean ages 18.4-23.8 years in a sample of non-Hispanic White individuals (n = 334), we tested if genotype at each CNR1 SNP was associated with both level and growth of cannabis use over time...
September 2017: Journal of Studies on Alcohol and Drugs
https://www.readbyqxmd.com/read/28926863/evaluation-of-cannabinoid-and-terpenoid-content-cannabis-flower-compared-to-supercritical-co2-concentrate
#16
Michelle Sexton, Kyle Shelton, Pam Haley, Mike West
A recent cannabis use survey revealed that 60% of cannabis users rely on smelling the flower to select their cannabis. Olfactory indicators in plants include volatile compounds, principally represented by the terpenoid fraction. Currently, medicinal- and adult-use cannabis is marketed in the United States with relatively little differentiation between products other than by a common name, association with a species type, and Δ-9 tetrahydrocannabinol/cannabidiol potency. Because of this practice, how terpenoid compositions may change during an extraction process is widely overlooked...
September 19, 2017: Planta Medica
https://www.readbyqxmd.com/read/28923526/results-of-a-double-blind-randomized-placebo-controlled-study-of-nabiximols-oromucosal-spray-as-adjunctive-therapy-in-advanced-cancer-patients-with-chronic-uncontrolled-pain
#17
Aron H Lichtman, Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, Marie T Fallon
CONTEXT: Prior phase 2/3 studies found that cannabinoids might provide adjunctive analgesia in advanced cancer patients with uncontrolled pain. OBJECTIVE: To assess adjunctive nabiximols (Sativex(®)), an extract of Cannabis sativa containing two potentially therapeutic cannabinoids (Δ9-tetrahydrocannabinol [27 mg/mL] and cannabidiol [25mg/mL]), in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy. METHODS: Phase 3, double-blind, randomized, placebo-controlled trial in patients with advanced cancer and average pain NRS scores ≥ 4 and ≤ 8 despite optimized opioid therapy...
September 15, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28921814/nabilone-pharmacotherapy-for-cannabis-dependence-a-randomized-controlled-pilot-study
#18
Kevin P Hill, Matthew D Palastro, Staci A Gruber, Garrett M Fitzmaurice, Shelly F Greenfield, Scott E Lukas, Roger D Weiss
BACKGROUND AND OBJECTIVES: We assessed the safety, tolerability, and preliminary efficacy of nabilone, a cannabinoid agonist, to treat cannabis dependence. METHODS: Eighteen adults with DSM-IV cannabis dependence were randomized to receive either 2 mg/day of nabilone (n = 10) or placebo (n = 8) for 10 weeks in addition to medication management. Twelve participants, six in each group, completed treatment. The safety and tolerability of nabilone was assessed at each visit...
September 18, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/28915313/a-metabolomic-approach-applied-to-a-liquid-chromatography-coupled-to-high-resolution-tandem-mass-spectrometry-method-hplc-esi-hrms-ms-towards-the-comprehensive-evaluation-of-the-chemical-composition-of-cannabis-medicinal-extracts
#19
Cinzia Citti, Umberto Maria Battisti, Daniela Braghiroli, Giuseppe Ciccarella, Martin Schmid, Maria Angela Vandelli, Giuseppe Cannazza
INTRODUCTION: Cannabis sativa L. is a powerful medicinal plant and its use has recently increased for the treatment of several pathologies. Nonetheless, side effects, like dizziness and hallucinations, and long-term effects concerning memory and cognition, can occur. Most alarming is the lack of a standardised procedure to extract medicinal cannabis. Indeed, each galenical preparation has an unknown chemical composition in terms of cannabinoids and other active principles that depends on the extraction procedure...
September 15, 2017: Phytochemical Analysis: PCA
https://www.readbyqxmd.com/read/28911631/new-psychoactive-substances-of-natural-origin-a%C3%A2-brief-review
#20
REVIEW
Ling-Yi Feng, Altansuvd Battulga, Eunyoung Han, Heesun Chung, Jih-Heng Li
Plant-based drugs of abuse are as old as recorded human history. Although traditional addictive substances, such as opium, cannabis and coca, have been controlled by the United Nations anti-drug conventions, many, if not most, natural plants with addictive or abuse liability remain elusive. Therefore, the United Nations Office on Drugs and Crime (UNODC) has warned the emerging threat from new psychoactive substances (NPS), which are mostly derived or modified from the constituents of natural origin. For example, synthetic cannabinoids and synthetic cathinones are derived from the cannabis and khat plant, respectively...
July 2017: Journal of Food and Drug Analysis
keyword
keyword
118095
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"